Team Newcastle


The Cancer Prevention Research Group, Newcastle University, has two primary aims: To improve the identification of individuals who would most benefit from cancer prevention, and to explore biological variation and clinical interventions associated with reduced cancer risk. These aims are supported by Cancer Research UK through the CaPP3 clinical trial (Cancer Prevention Project 3, ISRCTN 16261285), which is investigating the best dose of aspirin for cancer prevention in Lynch syndrome gene carriers, and the Aspirin for Cancer Prevention (AsCaP) Catalyst collaboration.


